Fennec Pharmaceuticals’ Cisplatin-Ototoxicity Treatment Given Breakthrough Therapy Designation

According to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.